Ingersoll-Rand Inc - IR STOCK NEWS

Ingersoll Rand has finalized the acquisition of ILC Dover for $2.325 billion, expanding its market reach to $65 billion. Additionally, the company acquired Complete Air and Power Solutions, Del PD Pumps & Gear Pvt , and Fruitland Manufacturing for $150 million. These acquisitions aim to enhance Ingersoll Rand's portfolio in sustainable markets such as life sciences, food and beverage, medical, and wastewater treatment. The company demonstrates its commitment to achieving mid-teens return on invested capital within three years post-acquisition.

Ingersoll Rand (NYSE: IR) announced that CFO Vik Kini and VP Matthew Fort will participate in the Wolfe 17th Annual Global Transportation and Industrials Conference. The event will take place on May 22, 2024, at 8:00 a.m. Eastern Time. A fireside chat will be webcast live and will be available for replay on the company's Investor Relations website. This participation highlights the company's ongoing engagement with investors and stakeholders, providing insights into its financial strategies and business outlook.

Ingersoll Rand Inc. successfully completed a $3,300 million Senior Unsecured Bond Offering and established a new $2,600 million Senior Unsecured Revolving Credit Facility. The funds raised will be used for various purposes, including the repayment of term loans, funding an acquisition, and general corporate uses. The company also received an upgrade in its credit ratings by all three major agencies, reflecting its strong financial performance and improved capital structure.

Ingersoll Rand has led a $19M financing round for Inkbit, a pioneer in advanced additive manufacturing solutions. The funding will advance Inkbit's Vision-Controlled Jetting™ (VCJ) technology, enabling rapid manufacturing of innovative products like complex industrial fluidics and bio-inspired robots. Inkbit's technology reimagines the traditional assembly line, combining scalability, reliability, and intelligence to build multi-functional products in one pass.

Ingersoll Rand reported record first quarter revenues, Adjusted EBITDA, and Adjusted EPS. The company raised its total company Adjusted EBITDA and Adjusted EPS guidance for 2024, showcasing a strong performance driven by Ingersoll Rand Execution Excellence (IRX). Despite a decline in orders, the two-year stack shows an improvement, with reported revenues and net income also on the rise. The company maintains a healthy liquidity of $3.5 billion and has raised its 2024 guidance for Adjusted EBITDA and Adjusted EPS. Ingersoll Rand is focused on delivering long-term value to shareholders through strategic acquisitions and comprehensive capital allocation strategies.

Ultima Genomics, a developer of an innovative ultra-high throughput sequencing architecture, announced the addition of Mark Stevenson, a seasoned executive with over 30 years of experience in the life sciences sector, to its Board of Directors. Stevenson, the former Executive Vice President and COO of Thermo Fisher Scientific, brings valuable expertise in next-generation sequencing technologies and innovation. His appointment is expected to bolster Ultima Genomics' position in the genomics and healthcare fields.

Ingersoll Rand Inc. (NYSE: IR) declares a regular quarterly cash dividend of $0.02 per share and increases share repurchase authorization by $1 billion. The dividend is payable on June 6, 2024, to shareholders of record on May 16, 2024. The company plans to utilize the existing repurchase authorization by the end of fiscal year 2024. The additional authorization aligns with Ingersoll Rand's capital allocation strategy and focus on creating shareholder value.

Ingersoll Rand Inc. (IR) will release its first quarter 2024 earnings on May 2, 2024. A live conference call to discuss the results will be held on May 3, 2024. Investors can participate via phone or webcast.

Ingersoll Rand (NYSE: IR) completes acquisitions of Controlled Fluidics and Ethafilter to enhance its life science and air treatment businesses. The acquisitions aim to boost market share, introduce new revenue streams, and expand into in-vitro diagnostics, genomics, and sterile filter technology markets. The company expects mid-teens return on invested capital by the third year of ownership.